Related Experiment Video
Updated: Jun 3, 2026
09:21
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis.
Vera Paulson1, Garvin Chandler, Dinesh Rakheja
1Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Genes, Chromosomes & Cancer
|March 18, 2011
Summary
Genomic analysis of intermediate-risk embryonal rhabdomyosarcoma (ERMS) reveals common defects. Key findings include CDKN2A/B inactivation, FGFR4 activation, and altered Ras and Hedgehog signaling, guiding targeted therapy development.
Area of Science:
- Genomics
- Pediatric Oncology
- Molecular Biology
Background:
- Pediatric rhabdomyosarcoma (ERMS) has distinct biological variants.
- Understanding genomic alterations in intermediate-risk ERMS is crucial for targeted therapy.
Purpose of the Study:
- To identify genomic changes driving ERMS pathogenesis in intermediate-risk patients.
- To investigate the role of specific genes and signaling pathways in ERMS development.
Main Methods:
- Utilized a high-resolution array comparative genomic hybridization (aCGH) platform.
- Examined a cohort of ERMS tumors from children with intermediate-risk disease.
- Analyzed genomic alterations including deletions, amplifications, and copy number gains.
Main Results:
- Frequent deletion of the CDKN2A/B tumor suppressor gene.
- Activation of FGFR4, Ras, and Hedgehog (Hh) signaling pathways observed in a significant subset of tumors.
- NF1 deletions and Ras mutations were mutually exclusive, indicating alternative Ras activation mechanisms.
Conclusions:
- Intermediate-risk ERMS is characterized by a common genomic program.
- Identified genomic defects provide potential targets for novel therapeutic strategies.
- Findings have implications for improving treatment outcomes in pediatric rhabdomyosarcoma.
